The US Government Just Bet $144 Million That Aging Is a Disease You Can Treat

The same government agency that helped create the internet just declared war on aging.

Last week, ARPA-H — the health-focused cousin of DARPA — committed up to $144 million to seven research teams with a single goal: prove that aging isn't something you endure. It's something you treat.

The program is called PROSPR (Proactive Solutions for Prolonging Resilience). It's the first coordinated federal effort to directly target the biology of aging rather than patching diseases one at a time after they arrive.

"PROSPR represents a tectonic shift in how we study healthy aging," said ARPA-H Director Dr. Alicia Jackson.

Here's why that sentence matters more than it sounds.

The problem nobody talks about

More than 90% of Americans over 65 live with at least one chronic condition. Around 80% have two or more. Life expectancy keeps rising. The years spent in good health haven't budged.

We've gotten better at keeping people alive. We haven't gotten better at keeping them well.

The entire medical system is built to treat diseases after they show up — diabetes, heart failure, Alzheimer's. Aging itself, the process that makes all of them more likely, has never been treated as a medical target. No FDA-approved drug exists to slow functional decline in healthy adults.

PROSPR wants to change that. And the drugs they're betting on are wild.

Three pills, seven teams, one question

The University of Texas Health Science Center at San Antonio got the biggest slice: up to $38 million for a trial called VITAL-H. They're testing three FDA-approved drugs on healthy adults aged 60 to 65.

The drugs: rapamycin, dapagliflozin, and semaglutide.

You've heard of semaglutide — it's the molecule behind Ozempic and Wegovy. Turns out its effects on inflammation and metabolic health go far beyond weight loss. Dapagliflozin is an SGLT2 inhibitor originally for diabetes. Rapamycin is an immunosuppressant discovered in Easter Island soil in the 1970s that keeps extending lifespan in lab animals.

All three are oral, well-studied, and have decades of safety data. The question isn't whether they work for their original purposes. It's whether they can slow aging itself.

The $30.8 million rapamycin upgrade

Cambrian BioPharma got $30.8 million for something more targeted. They're building a next-generation rapamycin analog that selectively blocks mTORC1 — a cellular pathway that acts like a growth switch.

When you're young, mTORC1 helps you build muscle and recover. As you age, it stays stuck in "go" mode, driving metabolic decline and inflammation. Existing rapamycin hits both mTORC1 and mTORC2 (the pathway you want left alone). Cambrian's version aims to hit only the one that's hurting you.

"The aging field has hotly debated mTORC inhibition because while existing drugs extend healthspan in animals, their low specificity comes with risks in humans," said ARPA-H program manager Dr. Andrew Brack. "That's why we're particularly excited to see the results of this new, specific mTORC1 inhibitor."

If it works, it's a daily pill that slows aging. That sentence would've sounded ridiculous five years ago.

Your DNA is attacking you (and there might be a fix)

The strangest bet in the program goes to the University of Rochester: up to $22 million to test whether HIV drugs can slow aging.

Not because aging is a virus. Because your own DNA starts acting like one.

Deep in your genome are fragments called LINE-1 retrotransposons — ancient viral remnants that make up about 17% of human DNA. For most of your life, they stay dormant. As you age, they wake up.

When LINE-1 elements activate, they trigger your immune system's antiviral defense. Your cells react as though they're fighting an infection that doesn't exist. The result: chronic inflammation — the kind linked to heart disease, neurodegeneration, and frailty.

Rochester researchers John Sedivy and Vera Gorbunova first showed that LINE-1 directly activates interferon signaling, the same system your body uses against actual viruses. Their idea: what if antiretroviral drugs — the same ones that suppress HIV — could also silence these rogue DNA elements?

The drugs already have decades of safety data in healthy people. If they quiet the false alarm, they could reduce the background inflammation that drives most age-related decline.

The catch: aging is slow, trials are expensive

Here's why nobody's done this before. Aging takes decades. Traditional clinical trials need measurable outcomes — disease diagnosis, disability, death. You can't run a 30-year trial on healthy 60-year-olds and wait to count who gets Alzheimer's.

PROSPR's solution: build better biomarkers. Stanford is getting funded to create a "healthspan score" by harmonizing existing datasets. Columbia is mining completed trials for biomarkers that respond early to interventions. The goal is surrogate endpoints that show results in one to three years.

If they pull it off, future aging trials become feasible. That infrastructure matters more than any single drug.

The rapamycin lottery

A reality check arrived the same week as the ARPA-H announcement. Researchers at the University of Sydney reanalyzed 167 studies across eight species and found that rapamycin and calorie restriction do extend lifespan — but the benefits vary wildly between individuals.

"Some individuals will be much longer lived, some will be a little longer lived and some might not live any longer than they would have anyway," said researcher Tahlia Fulton. "You've got a bit of a lottery happening."

Neither intervention "squared the survival curve" — the ideal where everyone lives healthy until a consistent age. Instead, the spread of outcomes was enormous. Some animals gained years. Others gained nothing.

That's exactly why PROSPR matters. If we can't predict who benefits, we need better biomarkers to find out early. The lottery only stays a lottery if you can't read the ticket.

What this actually means

Governments fund what they believe is possible. For decades, aging was filed under "inevitable." ARPA-H just moved it to "treatable."

The $144 million isn't enough to cure aging. It's enough to prove the concept: that healthy people can take existing drugs and measurably slow their biological decline within a few years.

If even one of these seven teams delivers clear results, it changes the conversation permanently. Aging stops being a philosophical category and becomes a clinical target.

The program name is PROSPR. The pun is intentional. Whether the science delivers remains the biggest open question in medicine.

But for the first time, someone's actually running the experiment.